Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 4/6 |
Past Performance | 6/6 |
Financial Health | 5/6 |
Dividends | 1/6 |
4013 Stock Overview
Dr. Sulaiman Al Habib Medical Services Group Company establishes, manages, and operates hospitals, general and specialized medical complexes, day surgery centers, and pharmaceutical facilities in Saudi Arabia.
Rewards
Risk Analysis
No risks detected for 4013 from our risk checks.
Dr. Sulaiman Al Habib Medical Services Group Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ر.س210.20 |
52 Week High | ر.س230.00 |
52 Week Low | ر.س148.00 |
Beta | 0.94 |
1 Month Change | 4.68% |
3 Month Change | -3.13% |
1 Year Change | 14.86% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 292.16% |
Recent News & Updates
Why Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013) Could Be Worth Watching
Let's talk about the popular Dr. Sulaiman Al Habib Medical Services Group Company ( TADAWUL:4013 ). The company's...
Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Has More To Do To Multiply In Value Going Forward
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Amongst other things, we'll want to...
Does Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Deserve A Spot On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
A Look At The Fair Value Of Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013)
Today we will run through one way of estimating the intrinsic value of Dr. Sulaiman Al Habib Medical Services Group...
Shareholder Returns
4013 | SA Healthcare | SA Market | |
---|---|---|---|
7D | -2.6% | -3.0% | -2.0% |
1Y | 14.9% | 15.1% | 19.2% |
Return vs Industry: 4013 matched the SA Healthcare industry which returned 15.1% over the past year.
Return vs Market: 4013 underperformed the SA Market which returned 19.2% over the past year.
Price Volatility
4013 volatility | |
---|---|
4013 Average Weekly Movement | 3.2% |
Healthcare Industry Average Movement | 4.6% |
Market Average Movement | 4.9% |
10% most volatile stocks in SA Market | 8.2% |
10% least volatile stocks in SA Market | 3.1% |
Stable Share Price: 4013 is less volatile than 75% of SA stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: 4013's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1993 | n/a | Nasser Mohammed Al Haqbani | https://www.hmg.com |
Dr. Sulaiman Al Habib Medical Services Group Company establishes, manages, and operates hospitals, general and specialized medical complexes, day surgery centers, and pharmaceutical facilities in Saudi Arabia. The company operates maternity, and orthopedics and spinal surgeries hospitals. It also operates dermatology, plastic surgery, ophthalmology, obesity treatment, and fertility centers, as well as pharmacies.
Dr. Sulaiman Al Habib Medical Services Group Fundamentals Summary
4013 fundamental statistics | |
---|---|
Market Cap | ر.س73.57b |
Earnings (TTM) | ر.س1.52b |
Revenue (TTM) | ر.س7.81b |
48.4x
P/E Ratio9.4x
P/S RatioIs 4013 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4013 income statement (TTM) | |
---|---|
Revenue | ر.س7.81b |
Cost of Revenue | ر.س5.26b |
Gross Profit | ر.س2.55b |
Other Expenses | ر.س1.02b |
Earnings | ر.س1.52b |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | 4.35 |
Gross Margin | 32.59% |
Net Profit Margin | 19.47% |
Debt/Equity Ratio | 55.6% |
How did 4013 perform over the long term?
See historical performance and comparisonDividends
1.6%
Current Dividend Yield71%
Payout RatioValuation
Is 4013 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4013?
Other financial metrics that can be useful for relative valuation.
What is 4013's n/a Ratio? | |
---|---|
n/a Ratio | 0x |
n/a | n/a |
Market Cap | ر.س73.57b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 9.5x |
Enterprise Value/EBITDA | 39.8x |
PEG Ratio | 4.6x |
Price to Earnings Ratio vs Peers
How does 4013's PE Ratio compare to its peers?
4013 PE Ratio vs Peers |
---|
Company | PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 59.5x | ||
4002 Mouwasat Medical Services | 40.4x | 13.6% | ر.س23.5b |
4004 Dallah Healthcare | 36.5x | 14.6% | ر.س10.5b |
4007 Al Hammadi Company For Development and Investment | 45.8x | 5.0% | ر.س6.6b |
4009 Middle East Healthcare | 115.2x | 32.7% | ر.س3.1b |
4013 Dr. Sulaiman Al Habib Medical Services Group | 48.4x | 10.5% | ر.س73.6b |
Price-To-Earnings vs Peers: 4013 is good value based on its Price-To-Earnings Ratio (48.4x) compared to the peer average (59.5x).
Price to Earnings Ratio vs Industry
How does 4013's PE Ratio compare vs other companies in the Asian Healthcare Industry?
Price-To-Earnings vs Industry: 4013 is expensive based on its Price-To-Earnings Ratio (48.4x) compared to the SA Healthcare industry average (38.5x)
Price to Earnings Ratio vs Fair Ratio
What is 4013's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 48.4x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 4013's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 4013 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 4013 (SAR210.2) is trading above our estimate of fair value (SAR186.74)
Significantly Below Fair Value: 4013 is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is lower than the current share price.
Discover undervalued companies
Future Growth
How is Dr. Sulaiman Al Habib Medical Services Group forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Future Growth Score
4/6Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
10.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4013's forecast earnings growth (10.5% per year) is above the savings rate (8.9%).
Earnings vs Market: 4013's earnings (10.5% per year) are forecast to grow faster than the SA market (0.9% per year).
High Growth Earnings: 4013's earnings are forecast to grow, but not significantly.
Revenue vs Market: 4013's revenue (13.1% per year) is forecast to grow faster than the SA market (-1.6% per year).
High Growth Revenue: 4013's revenue (13.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4013's Return on Equity is forecast to be high in 3 years time (28.5%)
Discover growth companies
Past Performance
How has Dr. Sulaiman Al Habib Medical Services Group performed over the past 5 years?
Past Performance Score
6/6Past Performance Score 6/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
19.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 4013 has high quality earnings.
Growing Profit Margin: 4013's current net profit margins (19.5%) are higher than last year (18.7%).
Past Earnings Growth Analysis
Earnings Trend: 4013's earnings have grown by 19% per year over the past 5 years.
Accelerating Growth: 4013's earnings growth over the past year (20.6%) exceeds its 5-year average (19% per year).
Earnings vs Industry: 4013 earnings growth over the past year (20.6%) exceeded the Healthcare industry 0.6%.
Return on Equity
High ROE: 4013's Return on Equity (26.6%) is considered high.
Discover strong past performing companies
Financial Health
How is Dr. Sulaiman Al Habib Medical Services Group's financial position?
Financial Health Score
5/6Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: 4013's short term assets (SAR4.4B) exceed its short term liabilities (SAR2.2B).
Long Term Liabilities: 4013's short term assets (SAR4.4B) exceed its long term liabilities (SAR3.8B).
Debt to Equity History and Analysis
Debt Level: 4013's net debt to equity ratio (7.6%) is considered satisfactory.
Reducing Debt: 4013's debt to equity ratio has increased from 26.6% to 55.6% over the past 5 years.
Debt Coverage: 4013's debt is well covered by operating cash flow (69.9%).
Interest Coverage: 4013's interest payments on its debt are well covered by EBIT (56.8x coverage).
Balance Sheet
Discover healthy companies
Dividend
What is Dr. Sulaiman Al Habib Medical Services Group current dividend yield, its reliability and sustainability?
Dividend Score
1/6Dividend Score 1/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
1.64%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 4013's dividend (1.64%) isn’t notable compared to the bottom 25% of dividend payers in the SA market (1.86%).
High Dividend: 4013's dividend (1.64%) is low compared to the top 25% of dividend payers in the SA market (4.2%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, 4013 has been paying a dividend for less than 10 years.
Growing Dividend: 4013's dividend payments have increased, but the company has only paid a dividend for 2 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonable payout ratio (71.1%), 4013's dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its high cash payout ratio (126%), 4013's dividend payments are not well covered by cash flows.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
0.6yrs
Average management tenure
CEO
Nasser Mohammed Al Haqbani
no data
Tenure
ر.س230,000
Compensation
Mr. Nasser Mohammed Abdulaziz Al Haqbani has been Chief Executive Officer and Executive Member of Board at Dr. Sulaiman Al Habib Medical Services Group Company since December 10, 2018 and also serves as it...
Leadership Team
Experienced Management: 4013's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.
Board Members
Experienced Board: 4013's board of directors are considered experienced (3.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Dr. Sulaiman Al Habib Medical Services Group Company's employee growth, exchange listings and data sources
Key Information
- Name: Dr. Sulaiman Al Habib Medical Services Group Company
- Ticker: 4013
- Exchange: SASE
- Founded: 1993
- Industry: Health Care Facilities
- Sector: Healthcare
- Implied Market Cap: ر.س73.570b
- Shares outstanding: 350.00m
- Website: https://www.hmg.com
Number of Employees
Location
- Dr. Sulaiman Al Habib Medical Services Group Company
- King Fahad Road
- Olaya District
- Riyadh
- 11372
- Saudi Arabia
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/08/19 00:00 |
End of Day Share Price | 2022/08/18 00:00 |
Earnings | 2022/06/30 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.